KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Non Operating Income: 2011-2024

Historic Non Operating Income for Sarepta Therapeutics (SRPT) over the last 14 years, with Dec 2024 value amounting to $42.7 million.

  • Sarepta Therapeutics' Non Operating Income fell 682.24% to -$83.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$47.0 million, marking a year-over-year decrease of 293.86%. This contributed to the annual value of $42.7 million for FY2024, which is 116.92% up from last year.
  • As of FY2024, Sarepta Therapeutics' Non Operating Income stood at $42.7 million, which was up 116.92% from -$252.3 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Non Operating Income registered a high of $42.7 million during FY2024, and its lowest value of -$252.3 million during FY2023.
  • In the last 3 years, Sarepta Therapeutics' Non Operating Income had a median value of -$153.8 million in 2022 and averaged -$121.1 million.
  • In the last 5 years, Sarepta Therapeutics' Non Operating Income surged by 233.44% in 2020 and then slumped by 651.79% in 2021.
  • Yearly analysis of 5 years shows Sarepta Therapeutics' Non Operating Income stood at $11.1 million in 2020, then plummeted by 651.79% to -$61.2 million in 2021, then plummeted by 151.09% to -$153.8 million in 2022, then crashed by 64.07% to -$252.3 million in 2023, then spiked by 116.92% to $42.7 million in 2024.